Neuren Pharmaceuticals Limited (ASX:NEU)
Australia · Delayed Price · Currency is AUD 20.54
+0.18 (0.88%)
Sep 17, 2026, 4:17 PM AEST
Neuren Pharmaceuticals Cash Flow Statement
Financials in millions AUD. Fiscal year is January - December.
Millions AUD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 20.26 | 30.44 | 142.04 | 157.08 | 0.18 | -7.79 |
Depreciation & Amortization | 0.03 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 |
Loss (Gain) From Sale of Investments | 5.38 | 3.3 | -3.59 | 1.53 | 0.7 | - |
Stock-Based Compensation | 4.8 | 3.67 | 1.23 | 2.93 | 1.99 | 0.84 |
Other Operating Activities | -6.91 | -8.03 | 10.44 | 0.14 | 0.18 | -0.4 |
Change in Accounts Receivable | 1.06 | 154.59 | -157.11 | -13.11 | 0.19 | -2.51 |
Change in Accounts Payable | 0.51 | -0.49 | -0.48 | - | 0.34 | -0.11 |
Change in Income Taxes | -14.32 | -48.91 | -3.83 | 36.35 | - | - |
Change in Other Net Operating Assets | -9.82 | -9.17 | - | - | - | - |
Operating Cash Flow | 5.12 | 125.42 | -11.27 | 184.93 | 3.6 | -9.97 |
Operating Cash Flow Growth | -96.28% | - | - | 5038.23% | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -0.04 | -0.04 | -0.01 | -0.04 | -0.02 | -0.01 |
Investment in Securities | 16.42 | -87.97 | 4.14 | -211.45 | - | - |
Investing Cash Flow | 16.38 | -88.01 | 4.13 | -211.49 | -0.02 | -0.01 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Issuance of Common Stock | 6.73 | 6.39 | 1.66 | 3.64 | - | 23.28 |
Repurchase of Common Stock | -3.88 | -39.57 | -10.43 | - | - | - |
Other Financing Activities | -0.03 | -0.04 | -0.01 | -0.02 | -0 | -1.11 |
Financing Cash Flow | 2.83 | -33.22 | -8.78 | 3.62 | -0 | 22.18 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | -3.28 | -3.12 | 1.97 | -0.15 | -0.18 | 0.4 |
Net Cash Flow | 21.04 | 1.07 | -13.94 | -23.09 | 3.4 | 12.6 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 5.08 | 125.39 | -11.28 | 184.89 | 3.58 | -9.98 |
Free Cash Flow Growth | -96.31% | - | - | 5064.39% | - | - |
Free Cash Flow Margin | 7.30% | 193.95% | -5.20% | 79.71% | 23.22% | -312.17% |
Free Cash Flow Per Share | 0.04 | 0.96 | -0.09 | 1.41 | 0.03 | -0.08 |
Levered Free Cash Flow | -13.55 | 116.98 | -42.25 | 152.97 | 2.59 | -6.76 |
Unlevered Free Cash Flow | -13.55 | 116.98 | -42.25 | 152.97 | 2.59 | -6.76 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash Income Tax Paid | 13.33 | 54.15 | 37.22 | -0.88 | -1.39 | -2.52 |
Change in Working Capital | -18.44 | 96.02 | -161.42 | 23.24 | 0.53 | -2.62 |